Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotic Supplementation During Chemotherapy for Colon Cancer
NCT06772090Not yet recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Modality
- Live Biotherapeutic Products
01
Overview
Randomised, single-blind trial of bifidobacterium + lactobacillus in colon cancer (3 arms), sponsored by Masonic Cancer Center. Primary endpoint: Number of Participants at end of study at 12 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
bifidobacterium + lactobacillus
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT06772090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06772090.